The Use of Drug-Coated Balloons for Patients with In-Stent Restenosis

  • Fernando Alfonso
  • Javier Cuesta
  • Fernando Rivero
  • Marcos García Guimaraes
  • Teresa Bastante
  • Bernardo Cortese


Most of the evidence supporting the efficacy and clinical value of drug-coated balloons (DCB) has been generated in patients suffering from in-stent restenosis (ISR) [1]. Other scenarios for the use of DCB include small vessels, diffuse disease, and coronary bifurcation where the systematic implantation of a stent is not very attractive or is associated with adverse clinical and angiographic results. Information on the value of DCB in these settings is mainly based in observational registries or small clinical trials. Some studies also suggest that DCB may be of value in patients with acute myocardial infarction, a complex scenario associated with plaque rupture and a large thrombus burden where the acute results of stent implantation may not be optimal. At last DCB have been used in selected de novo lesions providing satisfactory angiographic results obtained upon dilatation.


  1. 1.
    Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659–73.CrossRefGoogle Scholar
  2. 2.
    Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113–24.CrossRefGoogle Scholar
  3. 3.
    Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012;5:323–30.CrossRefGoogle Scholar
  4. 4.
    Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119:2986–94.CrossRefGoogle Scholar
  5. 5.
    Scheller B, Fontaine T, Mangner N, et al. A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: results from the multi-center randomized controlled PATENT-C first in human trial. Catheter Cardiovasc Interv. 2016;88(1):51–9.CrossRefGoogle Scholar
  6. 6.
    Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis intra-stent of bare metal stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63:1378–86.CrossRefGoogle Scholar
  7. 7.
    Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, et al. Long-term results of everolimus-eluting stents versus drug-eluting balloons in patients with bare-metal in-stent restenosis: 3-year follow-up of the RIBS V clinical trial. JACC Cardiovasc Interv. 2016;9:1246–55.CrossRefGoogle Scholar
  8. 8.
    Adriaenssens T, Dens J, Ughi G, Bennett J, et al. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomized clinical trial. EuroIntervention. 2014;10:439–48.CrossRefGoogle Scholar
  9. 9.
    Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis: the treatment of in-stent restenosis study. Circ Cardiovasc Interv. 2016;9:e003316.PubMedGoogle Scholar
  10. 10.
    Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4:149–54.CrossRefGoogle Scholar
  11. 11.
    Rittger H, Brachmann J, Sinha AM, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012;59:1377–82.CrossRefGoogle Scholar
  12. 12.
    Xu B, Gao R, Wang J, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014;7:204–11.CrossRefGoogle Scholar
  13. 13.
    Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381:461–7.CrossRefGoogle Scholar
  14. 14.
    Kufner S, Joner M, Schneider S, et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. JACC Cardiovasc Interv. 2017;10(13):1332–40.CrossRefGoogle Scholar
  15. 15.
    Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the ribs iv randomized clinical trial. J Am Coll Cardiol. 2015;66:23–33.CrossRefGoogle Scholar
  16. 16.
    Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386:655–64.CrossRefGoogle Scholar
  17. 17.
    Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRefGoogle Scholar
  18. 18.
    Wöhrle J, Zadura M, Möbius-Winkler S, et al. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol. 2012;60(18):1733–8.CrossRefGoogle Scholar
  19. 19.
    Habara S, Iwabuchi M, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J. 2013;166:527–533.e2.CrossRefGoogle Scholar
  20. 20.
    Habara S, Kadota K, Shimada T, et al. Late restenosis after paclitaxel-coated balloon angioplasty occurs in patients with drug-eluting stent restenosis. J Am Coll Cardiol. 2015;66:14–22.CrossRefGoogle Scholar
  21. 21.
    Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, et al. Usefulness of drug-eluting balloons for bare-metal and drug-eluting in-stent restenosis (from the RIBS IV and V randomized trials). Am J Cardiol. 2017;119:983–90.CrossRefGoogle Scholar
  22. 22.
    Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314–22.CrossRefGoogle Scholar
  23. 23.
    Sandoval J, Medina M, Alfonso F. Neointimal tissue healing patterns after paclitaxel-eluting balloon treatment of in-stent restenosis: optical coherence tomography and intravascular ultrasound insights. J Invasive Cardiol. 2012;24:E215–8.PubMedGoogle Scholar
  24. 24.
    Agostoni P, Belkacemi A, Voskuil M, Nathoe HM, Doevendans PA, Stella PR. Serial morphological and functional assessment of drug-eluting balloon for in-stent restenotic lesions: mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve. JACC Cardiovasc Interv. 2013;6(6):569–76.CrossRefGoogle Scholar
  25. 25.
    Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11:13–23.CrossRefGoogle Scholar
  26. 26.
    Hamm CW. Drug-coated balloons for the treatment of coronary in-stent restenosis: a randomised, multicenter, controlled clinical study. Presented at PCR 2017.Google Scholar
  27. 27.
    Alfonso F, Jimenez-Quevedo P, Gonzalo N, Medina M, Bañuelos C. Neoatherosclerosis after paclitaxel-coated balloon angioplasty for in-stent restenosis. Circulation. 2014;129:923–5.CrossRefGoogle Scholar
  28. 28.
    Alfonso F, Cuesta J, Pérez-Vizcayno MJ, et al. Bioresorbable vascular scaffolds for patients with in-stent restenosis: the RIBS VI study. JACC Cardiovasc Interv. 2017;10:1841–51.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Fernando Alfonso
    • 1
  • Javier Cuesta
    • 1
  • Fernando Rivero
    • 1
  • Marcos García Guimaraes
    • 1
  • Teresa Bastante
    • 1
  • Bernardo Cortese
    • 2
  1. 1.Department of CardiologyHospital Universitario La Princesa, Instituto Investigacion Sanitaria Princesa (IIS-IP), Universidad Autónoma de MadridMadridSpain
  2. 2.Cardiac DepartmentSan Carlo ClinicMilanoItaly

Personalised recommendations